William Blair: 'view BridgeBio as becoming a core smidcap biotech holding'

October 6, 2026 10:46 AM

William Blair analyst John Boyle reiterated an Outperform rating on BridgeBio Pharma (NASDAQ: BBIO).The analyst comments "For BridgeBio, while the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found